Clomiphene-associated combined hyperlipidemia: A case report

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 51, Issue 7, 2006, Pages 587-590

  Gillett, Melissa J ^a   Burnett, John R ^b   Yeap, Doreen ^b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b NONE

Author keywords

Clomiphene; Hyperlipidemia; Polycystic ovary syndrome

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CLOMIFENE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUPRORELIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; RECOMBINANT FOLLITROPIN; TRIACYLGLYCEROL;

ADULT; AMENORRHEA; ARTICLE; CASE REPORT; DISEASE PREDISPOSITION; DYSLIPIDEMIA; FAMILIAL DISEASE; FEMALE; FEMALE INFERTILITY; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; WITHDRAWAL BLEEDING;

ADULT; CLOMIPHENE; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERLIPOPROTEINEMIA TYPE III; LIPOPROTEINS; POLYCYSTIC OVARY SYNDROME; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33746256015     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Castro MR, Nguyen TT, O'Brien T: Clomiphene-induced severe hypertriglyceridemia and pancreatitis. Mayo Clin Proc 1999;74:1125-1128
2. Morello KC, Wurz GT, DeGregorio MW: SERMs: Current status and future trends. Crit Rev Oncol Hematol 2002;43:63-76
3. Hozumi Y, Kawano M, Salto T, et al: Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998;83:1633-1635
4. Joensuu H, Holli K, Oksanen H, et al: Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 2000;63:225-234
5. Hokansoh JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219
6. Yadav D, Pitchumoni CS: Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol 2003;36:54-62
7. Turner RT, Evans GL, Sluka JP, et al: Differential responses of estrogen target tissues in rats including bone to clomiphene, enclomiphene and zuclomiphene. Endocrinology 1998;139:3712-3720
8. Havel RJ, Rapaport E: Management of primary hyperlipidemia. New Engl J Med 1995;332:1491-1498
9. Knopp RH: Drug treatment of lipid disorders. New Engl J Med 1999;341:498-511
10. Mosca L, Harper K, Sarkar S, et al: Effect of raloxifene on serum triglycerides in postmenopausal women: Influence of predisposing factors for hypertriglyceridemia. Clin Ther 2001;23:1552-1565
11. Grey AB, Stapleton JP, Evans MC, et al: The effects of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995;80:3191-3195
12. Brun LD, Gagne C, Rousseau C, et al: Severe lipemia induced by tamoxifen. Cancer 1986;57:2123-2126
13. Kanel KT, Wolmark N, Thompson PD: Delayed severe hypertriglyceridaemia from tamoxifen. New Engl J Med 1997;337:281
14. Hozumi Y, Kawano M, Miyata M: Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocrine J 1997;44:745-749
15. Elisaf MS, Nakou K, Liamis G, et al: Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol 2000;11:1067-1069
16. Colls BM, George PM: Severe hypertriglyceridaemia and hypercholesterolaemia associated with tamoxifen use. Clin Oncol (R Coll Radiol) 1998;10:270-271
17. Eri LM, Urdal P, Bechensteen AG: Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995;154:100-104
18. Bostom AG, Gagnon DR, Cupples LA, et al: A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation 1994;90:1688-1695
19. Ricci G, Tamaro G, Simeone R, et al: Lipoprotein (a) changes during natural menstrual cycle and ovarian stimulation with recombinant and highly purified urinary FSH. Hum Reprod 2001;16:449-456
20. Brizzi P, Dessole S, Tonolo G, et al: Effect of ovarian stimulation on plasma lipid and apolipoprotein concentrations in a population of infertile women undergoing IVF/embryo transfer. Reprod Biomed Online 2003;6:309-312
21. Haines CJ, Cheung LP, Lam CW: Changes in atherogenic lipids and lipoproteins during natural and hyperstimulated cycles in healthy women. Fertil Steril 1997;68:231-235
22. van Bockxmeer FM, Mamotte CD: Apoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet 1992;340:879-880
23. von Eckardstein S, von Eckardstein A, Bender HG, et al: Elevated low-density lipoprotein-cholesterol in women with polycystic ovary syndrome. Gynecol Endocrinol 1996;10:311-318
24. Tsilchorozidou T, Overton C, Conway GS: The pathophysiology of polycystic ovary syndrome. Clin Endocrinol 2004;60:1-17